comparemela.com

Latest Breaking News On - Jilin cancer hospital - Page 5 : comparemela.com

Primary endpoint met in Phase III clinical trial of Trilaciclib in Chinese patients with small cell lung cancer

/PRNewswire/ On February 23 2022, Simcere Pharmaceutical Group (2096.HK) announced that the phase III clinical registration study of Trilaciclib in patients.

Ying chengBijoyesh mookerjeeChina national medical products administrationBoao lecheng international medical pilot zoneSimcere pharmaceutical groupProfessor ying chengJilin cancer hospitalChief medical officerPriority review designationDrug evaluationSimcere pharmaceutical group limitedHealth care amp hospitalsMedical pharmaceuticalsClinical trials amp medical discoveries

Primary endpoint met in Phase III clinical trial of Trilaciclib in Chinese patients with small cell lung cancer

/PRNewswire/ On February 23 2022, Simcere Pharmaceutical Group (2096.HK) announced that the phase III clinical registration study of Trilaciclib in patients.

Ying chengBijoyesh mookerjeeChina national medical products administrationBoao lecheng international medical pilot zoneSimcere pharmaceutical groupProfessor ying chengJilin cancer hospitalChief medical officerPriority review designationDrug evaluationSimcere pharmaceutical group limitedHealth care amp hospitalsMedical pharmaceuticalsClinical trials amp medical discoveries

Primary endpoint met in Phase III clinical trial of Trilaciclib in Chinese patients with small cell lung cancer

Press release content from PR Newswire. The AP news staff was not involved in its creation.

Ying chengHong kongBijoyesh mookerjeeChina national medical products administrationBoao lecheng international medical pilot zoneSimcere pharmaceutical groupDrug administrationProfessor ying chengJilin cancer hospitalChief medical officerPriority review designationDrug evaluationGreater chinaMainland chinaState drugPharmaceutical group

Investegate |Hutchmed China Ltd Announcements | Hutchmed China Ltd: HUTCHMED Initiates Phase I Trial of HMPL-653

Investegate |Hutchmed China Ltd Announcements | Hutchmed China Ltd: HUTCHMED Initiates Phase I Trial of HMPL-653
investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.

Cheng yingHong kongMark leeZhou yiAtholl tweedie freddy crossleyBen atwell alex shawAnnie chengChina limitedExchange commissionStock exchange of hong kongPhasei trialAdvanced malignant solid tumorsFlorham parkJilin cancer hospitalSecurities litigation reform actStock exchange

Henlius Phase 3 clinical study of novel PD-1 inhibitor serplulimab for the treatment of first-line extensive-stage small cell lung cancer (ES-SCLC) meets primary study endpoint

SHANGHAI, Dec. 7, 2021 /PRNewswire/ Shanghai Henlius Biotech, Inc. (2696.HK) announced that the first interim analysis met the primary study endpoint of the overall survival (OS) of the Phase

Ying chengJason zhuKostenloser wertpapierhandelJie wangGiorgio scagliottiDepartment of medical oncologyPrnewswire shanghai henlius biotech incCancer hospital chinese academy of medical sciencesUniversity of turinData monitoring committeeHenlius biotechIndependent data monitoring committeeMedical oncologyJilin cancer hospitalCancer hospital chinese academyMedical sciences

vimarsana © 2020. All Rights Reserved.